CTRI/2019/05/019022Completed未知
An Open label, Clinical Safety Study to evaluate the effectiveness of Kalimera hair oil on Human hair health for Hair Growth, Hair Strength, Hair Lustrous and Dandruff prevention
BioVein Innovations Solutions Private Limited0 sites50 target enrollmentStarted: TBDLast updated:
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 50
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
Inclusion Criteria
- •Male and female volunteers 18-50 years old, inclusive.
- •Able to provide informed consent after risks and benefits of the study have been explained.
- •Be willing to undergo all study procedures
- •Ability to communicate effectively with study personnel.
- •Agree to abstain from use of any hair growth affecting oral or topical medication including over the counter and herbal medications, minoxidil, finasteride or dutasteride during the course of this study; also agrees to abstain from shaving the head during the course of the study
Exclusion Criteria
- •Women who are pregnant or lactating.
- •Subjects who took any medicine which can affect the hair growth in recent 3 months.
- •Subjects who have used minoxidil or any oral or topical medication including over the counter and herbal medications for the treatment of hair loss within 6 months of study screening, or finasteride or dutasteride within 12 months of study screening.
- •Subjects with scalp / skin infection, history of hypersensitivity to study products which may interfere in the study.
- •Received any other investigational medicinal therapy within 30 days and topical therapy within 7 days prior to screening
- •Patient suffering from any active general illness or have history of any general illness.
Investigators
Similar Trials
Active, not recruiting
Phase 1
Clinical study to find out whether methylene blue injection is safe and effective in the treatment of a blood disorder (methemoglobinemia) resulting from exposure to toxic agents (drugs or environmental poisons)Acquired methemoglobinemiaMedDRA version: 20.0Level: LLTClassification code 10054290Term: Acquired methemoglobinemiaSystem Organ Class: 100000004851EUCTR2017-000290-37-GBProvepharm SAS10
Active, not recruiting
Phase 1
Clinical study to find out whether methylene blue injection is safe and effective in the treatment of a blood disorder (methemoglobinemia) resulting from exposure to toxic agents (drugs or environmental poisons)Acquired methemoglobinemiaMedDRA version: 20.0Level: LLTClassification code 10054290Term: Acquired methemoglobinemiaSystem Organ Class: 100000012871EUCTR2017-000290-37-FRProvepharm SAS10
Completed
Not Applicable
A clinical study to evaluate the glycemic index (glucose level in blood in 2 Hour period) and safety of COCOZEN in Human Volunteers.CTRI/2018/03/012389Akay Flavours and Aromatics Private Limited20
Not yet recruiting
Phase 4
Clinical efficacy and safety of Isha BalmCTRI/2018/02/011819Isha Arogya pvt ltd
Active, not recruiting
Phase 1
An open-label clinical study to evaluate the safety and antiepileptic activity of ganaxolaone in treatment of patients diagnosed with infantile spansms.EUCTR2006-004286-33-PLMarinus Pharmceuticals, Inc.54